SignalMacro

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

First-in-class approval targets underlying narcolepsy cause, a major regulatory milestone.

What changed

First-in-class approval targets underlying narcolepsy cause, a major regulatory milestone.

Why it matters

First-in-class approval targets underlying narcolepsy cause, a major regulatory milestone. — impact context not separately stored; see What changed.

Sources